About: Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 June 2018

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 2018 (uk) im August 2018 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 27 June 2018 (en) artículu científicu espublizáu en xunu de 2018 (ast)
publication date	wds:Q57171336-609CEC82-6741-4DAA-A746-0E8AEF7349FB
publication date	2018-06-27 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57171336-FE62A00A-7DB8-4F50-A191-E0397B478A01
language of work or name	English
cites work	wds:Q57171336-02AC8C8F-6417-4666-9623-9CAEC17F100C wds:Q57171336-058B5A7C-F26C-49F4-81FF-8B538793588C wds:Q57171336-07B36907-6A5E-42A0-BE9E-068C59C30175 wds:Q57171336-086C7016-942F-4DF6-8988-DB6F2FF20E81 wds:Q57171336-117024D3-E13C-4277-9C73-8FEF47D35B76 wds:Q57171336-13276274-E320-4476-B68E-F8F483151EAD wds:Q57171336-1D0626E2-847E-4C49-AFEE-CECA8D21F03B wds:Q57171336-1F0D8DF2-5071-4BB6-8290-EBB532018004 wds:Q57171336-2015F85F-6027-4728-8C08-561A4B0FB531 wds:Q57171336-249D3948-7A89-4B3D-ABEC-FB73F18CA57D wds:Q57171336-2BCD0631-8A02-4E7E-ADEA-779E5910D6DD wds:Q57171336-36A5D71F-27FF-41BE-B1C1-01D15603A86E wds:Q57171336-49604B43-E31F-4FF8-83B5-76068CD92225 wds:Q57171336-4FDEBF50-BC6C-4626-B1F6-E6D3D821E767 wds:Q57171336-554571B1-E82E-4740-8D05-89DDE16A1F10 wds:Q57171336-5C4FE510-16AC-482A-B566-6598F5F06C71 wds:Q57171336-61E7A780-E9B6-442D-BDD8-1730FEE4703A wds:Q57171336-64EE763C-9116-40E5-A9F0-679BCD897F75 wds:Q57171336-722627A1-5B2B-4062-AD9A-0D5EBEF0954A wds:Q57171336-7278C6F3-3797-4107-9BFB-8355E57FAC7B wds:Q57171336-73CFB746-6637-4DE3-A8B0-F6DFBA05E356 wds:Q57171336-73D5B1CB-D7CC-4348-8D85-1E301C62F28E wds:Q57171336-7C6100CA-6E4B-4C95-9FE8-52B7B9980D52 wds:Q57171336-96F69501-90B5-4390-A841-3914B6EDE3E2 wds:Q57171336-9B1E1C6D-ED4C-4F31-A589-37423D7EFF59 wds:Q57171336-A0D01F82-DAAA-4780-8043-A26931BECFC6 wds:Q57171336-A2696892-4740-4F1C-86AB-31B05492FA21 wds:Q57171336-A5BF144C-51A1-4567-9152-B45C81814288 wds:Q57171336-A6E6AFF8-6DE0-423C-889B-9F456F3A5606 wds:Q57171336-A7B76D89-D283-48A7-99A6-488EAD725E58 wds:Q57171336-AE75D911-98E7-4C4F-84DB-9995347EF4E2 wds:Q57171336-C7CF5B1A-8A1C-4E13-8E77-C01806F7496B wds:Q57171336-CBD43128-E707-4A7A-A383-6E3652D0AE05 wds:Q57171336-D04E8733-322B-45B7-AE09-2366F141499D wds:Q57171336-DF1C7817-FECB-452F-B48C-D93883EC8035 wds:Q57171336-E024DE2A-7A58-49F1-993C-FE50BE576AB5 wds:Q57171336-E56CAEB4-3733-4E2C-97C8-9353F51C93D7 wds:Q57171336-EAB6D2B5-468F-4B4F-BFB8-0225E9AB0F6D wds:Q57171336-EC865A7F-C609-4252-9E62-3EFF234DE064 wds:Q57171336-F125F2F3-9122-479C-9A4D-946A5D795930
cites work	Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta") Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase) 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. Cancer Statistics, 2017. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Localization of Recurrent Prostate Cancer After External Beam Radiotherapy F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer Actual impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients Proposal of a Structured Reporting System for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging: PSMA-RADS Version 1.0. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer BAY 1075553 PET-CT for Staging and Restaging Prostate Cancer Patients: Comparison with [18F] Fluorocholine PET-CT (Phase I Study) Cyclotron production of (68)Ga via the (68)Zn(p,n)(68)Ga reaction in aqueous solution
author name string	wds:Q57171336-012DE76E-8D32-44E1-85AD-C483ECD71AD8 wds:Q57171336-02468348-7B97-4182-9F14-60EEB2245BB3 wds:Q57171336-5E8CFCF4-51B9-4286-8AB4-31EC2A68394F wds:Q57171336-B6DC2420-925A-4D7E-BA66-60867831C497
author name string	Thomas A Hope Steven P Rowe Matthias Eiber Wolfgang P Fendler
rdfs:label	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications (en) Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications (nl)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software